Without a mandatory registration system, the companies would still have it in their interest to not publish certain trials.

253

It is ludicrous that the FDA could not find highly qualified experts in these fields who did not have ties to the manufacturer.

212

One could imagine prizes in the billions of dollars based on considerations such as the prevalence and public health impact of the disease, the difficulty in developing its cure, and the capital investment required to achieve results.

69